For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, ...

The use of anticoagulants offers significant benefits. They are indicated for various uses depending on the specific anticoagulant used, including: These medications protect individuals at high ...

Atrial fibrillation (AF) is a common heart condition that affects about one in three people at some point in their lives. It ...

Glenmark Pharmaceuticals has launched Phytonadione injectable emulsion through its US arm, targeting anticoagulant markets.

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

The true incidence of thrombosis among people who received targeted therapy for breast cancer is significantly higher than ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Objective: To provide recommendations, policies, and procedures pertaining to the provision of optimized anticoagulation therapy designed to achieve desired clinical endpoints while minimizing the ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Risk for bleeding events is significantly affected by DOAC score in patients with atrial fibrillation who have received TAVR.